Gepirone Under Review for Major Depressive Disorder
Exxua (previously named Travivo) is a novel oral serotonin 1A receptor agonist.
Diagnosis & Disease Information
Rykindo Approved for Schizophrenia, Bipolar Disorder
The approval was based on data from adequate and well-controlled studies with risperidone long-acting injection (intramuscular).
Brexpiprazole Gets Priority Review for Agitation With Alzheimer Dementia
The sNDA is supported by data from two phase 3 studies that evaluated the efficacy and safety of brexpiprazole in patients with agitation associated with Alzheimer dementia.
Iloperidone Benefits Patients With Bipolar I Disorder in Phase 3 Trial
The study included approximately 400 adults with a history of bipolar I disorder who had a current episode of mania.
Vraylar Approved as Adjunctive Therapy for Major Depressive Disorder
The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy.
Intranasal Therapy for Major Depressive Disorder Gets Fast Track Status
The designation is supported by data from 3 clinical studies.
Dextromethorphan-Bupropion Delays Relapse of Alzheimer Disease Agitation
AXS-05 is an investigational agent consisting of a proprietary formulation of dextromethorphan and bupropion.
Esketamine Nasal Spray Bests Quetiapine XR in Difficult-to-Treat Depression
The trial compared Spravato (esketamine nasal spray) to quetiapine extended-release, both in combination with a continuing SSRI or SNRI.
Jessica Peck, DNP, on How to Talk to Teens About Mental Health
Dr Jessica Peck provides practical tips for clinicians and parents on how to communicate with teenagers about mental health in Behind Closed Doors.
Smartphone Addiction: Tips for Assessment and Management
Determining when smartphone use has become an addiction in patients is tricky. Researchers outline what to look for.
- Loading...
Loading...
Next post in Medicine
Loading... 
Loading...